The purinergic P2X7 receptor is implicated in both neuropathic and inflammatory pain, and has been suggested as a possible target in pain treatment. However, the specific role of the P2X7 receptor in bone cancer pain is unknown. We demonstrated that BALB/cJ P2X7 receptor knockout (P2X7R KO) mice were susceptible to bone cancer pain and moreover had an earlier onset of pain-related behaviours compared with cancer-bearing, wild-type mice. Furthermore, acute treatment with the selective P2X7 receptor antagonist, A-438079, failed to alleviate pain-related behaviours in models of bone cancer pain with and without astrocyte activation (BALB/cJ or C3H mice inoculated with 4T1 mammary cancer cells or NCTC 2472 osteosarcoma cells, respectively), suggesting that astrocytic P2X7 receptors play a negligible role in bone cancer pain. The results support the hypothesis that bone cancer pain is a separate pain state compared with those of neuropathic and inflammatory pain. However, the recent discovery of a P2X7 receptor splice variant expressed in the knockout mice used for this study complicates the interpretation of the results. The P2X7 splice variant receptor was detected in the spinal cord but not in osteoclasts of the P2X7R KO mouse. Further experiments are needed to elucidate the exact role of the P2X7 receptors in bone cancer pain. Ó
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Introduction
Bone cancer pain is the most common pain in cancer patients [35] , and it can severely compromise the quality of life [10, 35] . In particular, breakthrough pain and incident pain is difficult to control, and the need for strong opiods increases as the bone cancer evolves [1,36,52]. The current treatment options for cancer-related bone pain leave some patients without adequate pain relief and are associated with dose limiting side effects [1,36]; therefore, new therapeutic options are needed. At the cellular level, bone cancer pain has components of both inflammatory and neuropathic pain but it is not yet fully classified. The spinal cord neurochemical changes seen in a murine model of bone cancer pain are distinct from those in neuropathic and inflammatory pain [25, 29] , suggesting that bone cancer pain is a separate pain state [7, 22] . One nociceptive pathway that has not been fully investigated in bone cancer pain is purinergic signalling.
ATP and other nucleotides are now regarded as neuromodulators, and their involvement in pain is well established [3, 16] . ATP acts as an agonist for 2 classes of receptors: ligand gated ion channels, the P2X receptors, and G-protein-coupled P2Y receptors [39] . The P2X7 receptor, one of the P2X receptors implicated in nociceptive signalling, has some distinguishing features. It requires high concentrations of ATP for activation (>100 lM), and upon prolonged ATP stimulation it is involved in the formation of pores that allow passage of large organic cations [39] . The implication of the P2X7 receptors in pain has been established in animal models of both neuropathic and inflammatory pain. Chessell et al. demonstrated that pain-related behaviours were absent in P2X7 receptor-deficient mice with neuropathic pain induced by partial nerve ligation, and that mechanical hypersensitivity was absent in inflammation induced by Complete Freund's adjuvant (CFA) [5] . In addition, several specific P2X7 receptor antagonists have proved effective in animal models of pain [27, 28, 34, 37] .
The P2X7 receptor has been hypothesized to be part of a common pathway in the central sensitization seen in chronic pain, as
